GKT137831: Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 (B4763, APExBIO) is a small-molecule inhibitor targeting NADPH oxidase isoforms Nox1 and Nox4, with Ki values of 140 nM and 110 nM, respectively (product_spec). It limits hypoxia-induced hydrogen peroxide (H2O2) release and cell proliferation in pulmonary vascular cells (internal_link). In animal studies, GKT137831 attenuates hepatic fibrosis, vascular remodeling, and diabetes-accelerated atherosclerosis by suppressing oxidative stress-mediated signaling (DOI). The compound is insoluble in water, but soluble at ≥39.5 mg/mL in DMSO. Standard cell-based assay concentrations range from 0.1 to 20 μM; animal dosing is 30–60 mg/kg/day by oral gavage (product_spec).

Biological Rationale

Reactive oxygen species (ROS) are central to cellular signaling and stress responses. NADPH oxidase enzymes, notably Nox1 and Nox4, catalyze ROS formation in vascular smooth muscle and endothelial cells. Overactivation of these isoforms is implicated in vascular remodeling, fibrosis, and atherosclerosis. Inhibiting Nox1/Nox4 reduces pathological H2O2 production and downstream pro-fibrotic and pro-inflammatory signaling (internal_link), extending the mechanistic discussion presented in prior reviews. GKT137831 enables precise interrogation of oxidative stress pathways by offering isoform-selective inhibition in research models (product_spec).

Mechanism of Action of GKT137831

GKT137831 selectively inhibits Nox1 and Nox4 catalytic activity with Ki values of 140 nM and 110 nM, respectively (product_spec). Nox1 predominantly resides in caveolar or endosomal membranes of vascular smooth muscle cells, while Nox4 localizes to the endoplasmic reticulum and nuclei (internal_link; this article clarifies molecular targeting compared to earlier reviews). The dual blockade suppresses ROS generation, thus dampening hypoxia-induced H2O2 release, cell proliferation, and TGF-β1 induction. GKT137831 also modulates PPARγ expression, impacting cellular redox balance. By interrupting Akt/mTOR and NF-κB signaling, the compound inhibits downstream pathologies such as fibrosis and vascular remodeling (DOI).

Evidence & Benchmarks

• GKT137831 inhibits Nox1 with a Ki of 140 nM and Nox4 with a Ki of 110 nM under in vitro conditions (source: product_spec).
• In human pulmonary artery endothelial and smooth muscle cells, GKT137831 at 1–10 μM reduces hypoxia-induced proliferation and H2O2 generation (source: internal_link).
• Animal dosing at 30–60 mg/kg/day by oral gavage mitigates hepatic fibrosis and vascular remodeling in rodent models (source: product_spec).
• GKT137831 suppresses diabetes mellitus-accelerated atherosclerosis by inhibiting oxidative stress-mediated pathways, as demonstrated by reduced lesion size and improved vascular function (source: DOI).
• Solubility benchmarks: soluble at ≥39.5 mg/mL in DMSO, ≥2.96 mg/mL in ethanol after warming and sonication. Compound is insoluble in water (source: product_spec).

Applications, Limits & Misconceptions

GKT137831 is broadly applied in studies of inhibition of reactive oxygen species production, attenuation of pulmonary vascular remodeling, and liver fibrosis treatment research. It is not approved for diagnostic or therapeutic use in humans. The compound’s selectivity for Nox1/Nox4 makes it unsuitable for models where Nox2- or Nox5-derived ROS predominate (internal_link). For deeper mechanistic context, see "Lipid Scrambling in Ferroptosis: TMEM16F as a Key Regulator" (internal_link); this article extends that discussion to the upstream redox drivers targeted by GKT137831.

Common Pitfalls or Misconceptions

• GKT137831 does not inhibit Nox2 or Nox5 isoforms; using it to target these enzymes may yield misleading results (source: product_spec).
• The compound is insoluble in water; improper solvent choice may lead to inaccurate dosing or precipitation (source: product_spec).
• Long-term storage of solutions is not recommended due to potential degradation (source: product_spec).
• GKT137831 is for research use only and not for diagnostic or clinical application (source: product_spec).
• Assuming all NADPH oxidase inhibitors act similarly can misguide experimental interpretation; GKT137831 is selective for Nox1 and Nox4 only.

Workflow Integration & Parameters

Protocol Parameters

• cell-based assay | 0.1–20 μM | in vitro Nox1/Nox4 inhibition | enables dose-response and pathway analysis in pulmonary and vascular cells | product_spec
• animal dosing | 30–60 mg/kg/day, oral gavage or intragastric | rodent models of fibrosis, atherosclerosis | benchmarks efficacy in vivo for translational research | product_spec
• solubility in DMSO | ≥39.5 mg/mL | stock solution preparation | ensures high-concentration stock for titration | product_spec
• solubility in ethanol | ≥2.96 mg/mL (with warming/sonic) | alternative solvent for specific assays | facilitates use in ethanol-compatible protocols | product_spec
• storage | -20°C, avoid long-term solutions | all workflows | preserves compound integrity | product_spec
• water solubility | insoluble | not recommended for aqueous prep | prevents precipitation and activity loss | product_spec

Conclusion & Outlook

GKT137831, supplied by APExBIO, is a reference dual NADPH oxidase Nox1/Nox4 inhibitor for oxidative stress research. Its nanomolar potency, validated selectivity, and robust in vitro and in vivo benchmarks enable translational studies in fibrosis, vascular remodeling, and diabetes-accelerated atherosclerosis. Researchers should adhere to solubility and storage recommendations to ensure data integrity. Emerging studies on lipid peroxidation and membrane remodeling, such as the role of TMEM16F in ferroptosis (DOI), underscore the importance of redox modulation at multiple cellular levels. GKT137831 remains a gold-standard tool for dissecting Nox1/Nox4-driven pathologies, providing a foundation for future mechanistic and translational advancements.